Thermo Cardiosystems says HeartMate sales set for record:
This article was originally published in Clinica
Executive Summary
Thermo Cardiosystems is predicting a buoyant fourth quarter with sales up more than 15% over the previous quarter to $17 million. Its HeartMate left ventricular assist system (LVAS) sales have risen over 35% in the same period, to $7 million. The HeartMate is the only LVAS system approved in the US. Thermo Cardiosystems, which is a subsidiary of Thermo Electron, reports its full year figures in February.
You may also be interested in...
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Medtech Industry Favorite Wins Seat On Powerful House E&C Committee
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: